{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T15:14:16Z","timestamp":1772205256456,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40268-023-00450-6","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T15:03:08Z","timestamp":1701097388000},"page":"51-68","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug\u2013Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7441","authenticated-orcid":false,"given":"Nicola","family":"Ferri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Stuart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Traversa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Folli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pappagallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedric","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"Guidetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Mattarei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles E.","family":"Inturrisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo L.","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"450_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2147\/NDT.S157708","volume":"14","author":"Y Low","year":"2018","unstructured":"Low Y, Setia S, Lima G. Drug-drug interactions involving antidepressants: focus on desvenlafaxine. Neuropsychiatr Dis Treat. 2018;14:567\u201380.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"450_CR2","doi-asserted-by":"publisher","first-page":"11389","DOI":"10.1038\/s41598-022-15055-3","volume":"12","author":"J Henningfield","year":"2022","unstructured":"Henningfield J, Gauvin D, Bifari F, Fant R, Shram M, Buchhalter A, et al. REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats. Sci Rep. 2022;12(1):11389.","journal-title":"Sci Rep"},{"key":"450_CR3","unstructured":"Shram M, Henningfield J, Apseloff G, Gorodetzky C, De Martin S, Vocci F, et al. No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant. Presented at: American Society of Clinical Psychopharmacology (ASCP) Annual Meeting; Scottsdale (AZ); 31, 2022."},{"issue":"7","key":"450_CR4","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3390\/ph15070882","volume":"15","author":"E Bettini","year":"2022","unstructured":"Bettini E, De Martin S, Mattarei A, Pappagallo M, Stahl SM, Bifari F, et al. The N-methyl-d-aspartate receptor blocker REL-1017 (esmethadone) reduces calcium influx induced by glutamate, quinolinic acid, and gentamicin. Pharmaceuticals (Basel). 2022;15(7):882.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"450_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/ph15080997","volume":"15","author":"E Bettini","year":"2022","unstructured":"Bettini E, Stahl SM, De Martin S, Mattarei A, Sgrignani J, Carignani C, et al. Pharmacological comparative characterization of REL-1017 (esmethadone-HCl) and other NMDAR channel blockers in human heterodimeric N-methyl-d-aspartate receptors. Pharmaceuticals (Basel). 2022;15(8):997.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"450_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1176\/appi.ajp.2021.21020197","volume":"179","author":"M Fava","year":"2022","unstructured":"Fava M, Stahl S, Pani L, De Martin S, Pappagallo M, Guidetti C, et al. REL-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2a randomized double-blind trial. Am J Psychiatry. 2022;179(2):122\u201331.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"450_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JCP.0000000000001035","volume":"39","author":"G Bernstein","year":"2019","unstructured":"Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Oldenhof J, et al. Characterization of the safety and pharmacokinetic profile of D-methadone, a novel N-methyl-d-aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies. J Clin Psychopharmacol. 2019;39(3):226\u201337.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"450_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/BF00542102","volume":"20","author":"U Meresaar","year":"1981","unstructured":"Meresaar U, Nilsson MI, Holmstrand J, Anggard E. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol. 1981;20(6):473\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"450_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/BF00315479","volume":"44","author":"K Wolff","year":"1993","unstructured":"Wolff K, Hay AW, Raistrick D, Calvert R. Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol. 1993;44(2):189\u201394.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"450_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1365-2125.1997.t01-1-00591.x","volume":"44","author":"K Wolff","year":"1997","unstructured":"Wolff K, Rostami-Hodjegan A, Shires S, Hay AW, Feely M, Calvert R, et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol. 1997;44(4):325\u201334.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"450_CR11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/00007691-199606000-00001","volume":"18","author":"K Kristensen","year":"1996","unstructured":"Kristensen K, Blemmer T, Angelo HR, Christrup LL, Drenck NE, Rasmussen SN, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit. 1996;18(3):221\u20137.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"450_CR12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/BF00548404","volume":"22","author":"MI Nilsson","year":"1982","unstructured":"Nilsson MI, Anggard E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase. Eur J Clin Pharmacol. 1982;22(4):343\u20139.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"450_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0304-3959(86)90234-4","volume":"25","author":"GK Gourlay","year":"1986","unstructured":"Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer. Pain. 1986;25(3):297\u2013312.","journal-title":"Pain"},{"issue":"2","key":"450_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1056-8719(00)00043-5","volume":"42","author":"MJ Garrido","year":"1999","unstructured":"Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic\/pharmacodynamic properties. J Pharmacol Toxicol Methods. 1999;42(2):61\u20136.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"450_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00004714-199512000-00002","volume":"15","author":"TA Ketter","year":"1995","unstructured":"Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol. 1995;15(6):387\u201398.","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"450_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00005110-199712000-00003","volume":"27","author":"NB Moody","year":"1997","unstructured":"Moody NB, Smith PL. Proactive changes in nursing work force development in Tennessee. J Nurs Adm. 1997;27(12):4\u20137.","journal-title":"J Nurs Adm"},{"issue":"1","key":"450_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/chir.10303","volume":"16","author":"JG Gerber","year":"2004","unstructured":"Gerber JG, Rhodes RJ, Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality. 2004;16(1):36\u201344.","journal-title":"Chirality"},{"issue":"2","key":"450_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1021\/tx950116m","volume":"9","author":"C Iribarne","year":"1996","unstructured":"Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996;9(2):365\u201373.","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"450_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1046\/j.1365-2125.1999.00921.x","volume":"47","author":"DJ Foster","year":"1999","unstructured":"Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol. 1999;47(4):403\u201312.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"450_CR20","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1124\/dmd.31.6.742","volume":"31","author":"JS Wang","year":"2003","unstructured":"Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos. 2003;31(6):742\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"450_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","volume":"76","author":"ED Kharasch","year":"2004","unstructured":"Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004;76(3):250\u201369.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"450_CR22","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/01.qai.0000219769.89679.ec","volume":"41","author":"RD Bruce","year":"2006","unstructured":"Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr. 2006;41(5):563\u201372.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"450_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00126334-200106010-00010","volume":"27","author":"JG Gerber","year":"2001","unstructured":"Gerber JG, Rosenkranz S, Segal Y, Aberg J, D\u2019Amico R, Mildvan D, et al. Effect of ritonavir\/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. A cquir Immune Defic Syndr. 2001;27(2):153\u201360.","journal-title":"A cquir Immune Defic Syndr."},{"issue":"4","key":"450_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/clpt.2008.104","volume":"84","author":"ED Kharasch","year":"2008","unstructured":"Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther. 2008;84(4):497\u2013505.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"450_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.12.009","volume":"101","author":"ED Kharasch","year":"2009","unstructured":"Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend. 2009;101(3):158\u201368.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"450_CR26","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1097\/ALN.0b013e3181986a9a","volume":"110","author":"ED Kharasch","year":"2009","unstructured":"Kharasch ED, Hoffer C, Whittington D, Walker A, Bedynek PS. Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir\/indinavir. Anesthesiology. 2009;110(3):660\u201372.","journal-title":"Anesthesiology"},{"issue":"15","key":"450_CR27","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1097\/01.aids.0000183628.20041.f2","volume":"19","author":"G Friedland","year":"2005","unstructured":"Friedland G, Andrews L, Schreibman T, Agarwala S, Daley L, Child M, et al. Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction. AIDS. 2005;19(15):1635\u201341.","journal-title":"AIDS"},{"key":"450_CR28","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: clinical drug interaction studies: cytochrome P450 enzyme- and transporter-mediated drug interactions. 2020. https:\/\/www.fda.gov\/media\/134581\/download. Accessed 13 Nov 2023."},{"issue":"5","key":"450_CR29","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1046\/j.1365-2125.2000.00272.x","volume":"50","author":"DJ Foster","year":"2000","unstructured":"Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol. 2000;50(5):427\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"450_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1124\/dmd.115.068601","volume":"44","author":"HQ Nguyen","year":"2016","unstructured":"Nguyen HQ, Kimoto E, Callegari E, Obach RS. Mechanistic modeling to predict midazolam metabolite exposure from in vitro data. Drug Metab Dispos. 2016;44(5):781\u201391.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"450_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/clpt.1992.84","volume":"51","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Tuk B, van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(6):715\u201328.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"450_CR32","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1124\/dmd.110.032649","volume":"38","author":"M Gertz","year":"2010","unstructured":"Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos. 2010;38(7):1147\u201358.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"450_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","volume":"75","author":"O von Richter","year":"2004","unstructured":"von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004;75(3):172\u201383.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"450_CR34","first-page":"1552","volume":"283","author":"MF Paine","year":"1997","unstructured":"Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther. 1997;283(3):1552\u201362.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"450_CR35","first-page":"1021","volume":"298","author":"Y Oda","year":"2001","unstructured":"Oda Y, Kharasch ED. Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001;298(3):1021\u201332.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"450_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1177\/009127000004000108","volume":"40","author":"CL Alfaro","year":"2000","unstructured":"Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol. 2000;40(1):58\u201366.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"450_CR37","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/bcp.13936","volume":"85","author":"C Victorri-Vigneau","year":"2019","unstructured":"Victorri-Vigneau C, Verstuyft C, Bouquie R, Laforgue EJ, Hardouin JB, Leboucher J, et al. Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study. Br J Clin Pharmacol. 2019;85(7):1538\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"450_CR38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","volume":"164","author":"CP Taylor","year":"2016","unstructured":"Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use. Pharmacol Ther. 2016;164:170\u201382.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"450_CR39","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1124\/dmd.30.12.1512","volume":"30","author":"A Galetin","year":"2002","unstructured":"Galetin A, Clarke SE, Houston JB. Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002;30(12):1512\u201322.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"450_CR40","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/ALN.0b013e3182423478","volume":"116","author":"ED Kharasch","year":"2012","unstructured":"Kharasch ED, Bedynek PS, Hoffer C, Walker A, Whittington D. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A). Anesthesiology. 2012;116(2):432\u201347.","journal-title":"Anesthesiology"},{"issue":"1","key":"450_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1124\/jpet.106.117580","volume":"321","author":"RA Totah","year":"2007","unstructured":"Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther. 2007;321(1):389\u201399.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"450_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jcph.1","volume":"53","author":"ED Kharasch","year":"2013","unstructured":"Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol. 2013;53(3):305\u201313.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"450_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/JCP.0b013e318222b5dd","volume":"31","author":"SC Wang","year":"2011","unstructured":"Wang SC, Ho IK, Tsou HH, Tian JN, Hsiao CF, Chen CH, et al. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. J Clin Psychopharmacol. 2011;31(4):463\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"450_CR44","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1124\/dmd.115.064352","volume":"43","author":"S Gadel","year":"2015","unstructured":"Gadel S, Friedel C, Kharasch ED. Differences in methadone metabolism by CYP2B6 variants. Drug Metab Dispos. 2015;43(7):994\u20131001.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"450_CR45","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1097\/ALN.0000000000000867","volume":"123","author":"ED Kharasch","year":"2015","unstructured":"Kharasch ED, Regina KJ, Blood J, Friedel C. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology. 2015;123(5):1142\u201353.","journal-title":"Anesthesiology"},{"issue":"4","key":"450_CR46","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/03602532.2019.1670204","volume":"51","author":"N Brosseau","year":"2019","unstructured":"Brosseau N, Ramotar D. The human organic cation transporter OCT1 and its role as a target for drug responses. Drug Metab Rev. 2019;51(4):389\u2013407.","journal-title":"Drug Metab Rev"},{"issue":"6","key":"450_CR47","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/pharmaceutics14061120","volume":"14","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A. Drug\u2013drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. 2022;14(6):1120.","journal-title":"Pharmaceutics"},{"issue":"5","key":"450_CR48","doi-asserted-by":"publisher","first-page":"587","DOI":"10.3109\/00952990.2016.1172078","volume":"42","author":"Z Zahari","year":"2016","unstructured":"Zahari Z, Lee CS, Ibrahim MA, Musa N, Mohd Yasin MA, Lee YY, et al. Relationship between ABCB1 polymorphisms and serum methadone concentration in patients undergoing methadone maintenance therapy (MMT). Am J Drug Alcohol Abuse. 2016;42(5):587\u201396.","journal-title":"Am J Drug Alcohol Abuse"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00450-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00450-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00450-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T04:17:06Z","timestamp":1713845826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00450-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,27]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["450"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00450-6","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,27]]},"assertion":[{"value":"2 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was sponsored by Relmada Therapeutics, Inc., Coral Gables, FL, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sara De Martin received personal fees from Relmada Therapeutics and from Aesculapius Farmaceutici. Marco Pappagallo received personal fees from Relmada Therapeutics during this study, he holds stock ownership with Acadia, and he has received personal fees from Overlook Medical Center. Andrea Mattarei and Franco Folli received personal fees from Relmada Therapeutics. Sergio Traversa, Charles E. Inturrisi, and Paolo L. Manfredi received personal fees and or held stock ownership from Relmada Therapeutics. Sergio Traversa is an employee of Relmada Therapeutics. Paolo L. Manfredi and Charles E. Inturrisi are inventors on patents related to esmethadone. Clotilde Guidetti has received personal fees from MGGM Therapeutics. James Stuart received fees from Relmada as a paid consultant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}